Larimar Therapeutics (LRMR) EBITDA (2013 - 2026)
Larimar Therapeutics (LRMR) EBITDA from Jun 30, 2013 to Mar 31, 2026. The TTM Larimar Therapeutics (LRMR) EBITDA is -$172M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Larimar Therapeutics (LRMR) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +63.86% |
| 3 Years TTM | +70.09% |
| 5 Years TTM | +29.08% |
| 10 Years TTM | +8.19% |
| All Time TTM | +23.82% |
Annual EBITDA change of Larimar Therapeutics (LRMR)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$31M | -81.96% |
| 2025 | -$172M | +90.07% |
| 2024 | -$91M | +118.50% |
| 2023 | -$41M | +14.47% |
| 2022 | -$36M | -27.78% |
| 2021 | -$50M | +17.56% |
| 2020 | -$43M | +84.31% |
| 2019 | -$23M | -61.98% |
| 2018 | -$61M | +15.24% |
| 2017 | -$53M | -8.96% |
| 2016 | -$58M | -21.33% |
| 2015 | -$74M | +107.60% |
| 2014 | -$36M | +157.95% |
| 2013 | -$14M | -0.07% |
| 2012 | -$14M | N/A |
Comparison Larimar Therapeutics (LRMR) five years EBITDA CAGR with competitors
Larimar Therapeutics (LRMR) five years EBITDA CAGR is 29.08%.